Donald Trump's personal spiritual adviser has sparked backlash after comparing the billionaire president's life to that of Jesus Christ’s, during an Easter lunch event at the White House. Paula ...

A massive new study comparing more than 100,000 people with today’s most advanced AI systems delivers a surprising result: generative AI can now beat the average human on certain creativity tests.

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. In case ...

This “dream wish list for criminals” includes millions of Gmail, Facebook, banking logins, and more. The researcher who discovered it suspects they were collected using infostealing malware. The ...

Nvidia’s Blackwell systems sales are “off the charts” according to CEO Jensen Huang, but analysts see fast growth for custom AI chips, known as ASICs. These smaller, cheaper, more narrowly focused AI ...

I suspect many TidBITS readers are of the generation that still uses the iPhone as a phone. Heck, many of us remember rotary phones that needed actual dialing, and some may even have had party lines, ...

The Python Software Foundation (PSF) has withdrawn its $1.5 million grant proposal to the U.S. National Science Foundation (NSF) due to funding terms forcing a compromise on its commitment to ...

We’re celebrating 180 years of Scientific American. Explore our legacy of discovery and look ahead to the future. Travel involves two main expenditures of energy: fighting gravity and propelling ...

It’s easy to get caught up in technology wars—Python versus Java versus NextBigLanguage—but the hardest part of AI isn’t the tools, it’s the people. Domain knowledge, skills, and adoption matter more ...

In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492), polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) showed a significant progression-free ...